Telaprevir for previously untreated chronic hepatitis C virus infection.

Abstract

BACKGROUND In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients. METHODS In this international, phase 3, randomized… (More)
DOI: 10.1056/NEJMoa1012912

Topics

6 Figures and Tables

Cite this paper

@article{Jacobson2011TelaprevirFP, title={Telaprevir for previously untreated chronic hepatitis C virus infection.}, author={I M for the New Paradigm of HCV Therapy Meeting Participants Jacobson and John McHutchison and Geoffrey Dusheiko and Adrian M Di Bisceglie and K R Reddy and Natalie H. Bzowej and Patrick Marcellin and Andrew Muir and P{\'e}ter Ferenci and Robert Flisiak and Jacob George and Mario Rizzetto and Daniel Shouval and Ricard Sol{\'a} and Ruben A Terg and Eric M Yoshida and Nathalie Adda and Leif Bengtsson and Abdul J Sankoh and Tara L. Kieffer and Shelley George and Robert S. Kauffman and Stefan Zeuzem}, journal={The New England journal of medicine}, year={2011}, volume={364 25}, pages={2405-16} }